Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMD8Q3J)

Drug Name
Gemfibrozil Drug Info
Synonyms
ApoGemfibrozil; Ausgem; Bolutol; Brozil; Cholespid; Clearol; Decrelip; Elmogan; Fetinor; Fibratol; Fibrocit; GFZ; Gemd; Gemfibril; Gemfibromax; Gemfibrosil; Gemfibrozilo; Gemfibrozilum; Gemhexal; Gemlipid; Gemnpid; GenGemfibrozil; Genlip; Gozid; Hidil; Hipolixan; Innogem; Innogen; Ipolipid; Jezil; Lanaterom; Lifibron; Lipazil; Lipigem; Lipira; Lipizyl; Lipozid; Lipur; Litarek; Lopid; Micolip; Normolip; NuGemfibrozil; Pilder; Polyxit; Progemzal; Reducel; Regulip; Renabrazin; Sinelip; Synbrozil; Taborcil; Tentroc; Trialmin; Alphapharm Brand of Gemfibrozil; Apo Gemfibrozil; Apotex Brand of Gemfibrozil; Bayvit Brand of Gemfibrozil; Bexal Brand of Gemfibrozil; Biochemie Brand of Gemfibrozil; Bull Brand of Gemfibrozil; Cantabria Brand of Gemfibrozil; Chem mart Brand of Gemfibrozil; Chem mart Gemfibrozil; DBL Gemfibrozil; Douglas Brand of Gemfibrozil; Farmasierra Brand of Gemfibrozil; Faulding Brand of Gemfibrozil;Ferrer Brand of Gemfibrozil; Gemfibrozilo Bayvit; Gemfibrozilo Bexal; Gemfibrozilo Ur; Gen Gemfibrozil; GenRX Gemfibrozil; Genpharm Brand of Gemfibrozil; Gevilon Uno; Healthsense Brand of Gemfibrozil; Healthsense Gemfibrozil; Hexal Brand of Gemfibrozil; Ipsen Brand of Gemfibrozil; Lipox Gemfi; Lopid R; Menarini Brand of Gemfibrozil; Novo Gemfibrozil; Novopharm Brand of Gemfibrozil; Nu Gemfibrozil; Nu Pharm Brand of Gemfibrozil; PMS Gemfibrozil; Parke Davis Brand of Gemfibrozil; Pfizer Brand of Gemfibrozil; Pharmascience Brand of Gemfibrozil; Quimifar Brand of Gemfibrozil; SBPA Gemfibrozil; Sigma Brand of Gemfibrozil; TAD Brand of Gemfibrozil; Terry White Chemists Brand of Gemfibrozil; Terry White Chemists Gemfibrozil; United Drug Brand of Gemfibrozil; Warner Lambert Brand of Gemfibrozil; CI719; Gemfi 1A Pharma; Apo-Gemfibrozil; Bayvit, Gemfibrozilo; Gem-S; Gemfibrozil, GenRX; Gemfibrozil, Healthsense; Gemfibrozil, SBPA; Gemfibrozilo [INN-Spanish]; Gemfibrozilum [INN-Latin]; Gen-Fibro;Gen-Gemfibrozil; Jezil (TN); Lopid (TN); Low-Lip; Novo-Gemfibrozil; Nu-Gemfibrozil; Nu-Pharm Brand of Gemfibrozil; PMS-Gemfibrozil; TEVA-A; WL-Gemfibrozil; Warner-Lambert Brand of Gemfibrozil; GEMFIBROZIL (SEE ALSO PEROXISOME PROJECT (GEMFIBROZIL)); Gemfibrozil [USAN:BAN:INN]; Gen-Fibro (TN); PEROXISOME PROJECT (GEMFIBROZIL) (SEE ALSO GEMFIBROZIL); Gemfibrozil (JAN/USP/INN); Gemcor, Lopid, Jezil,Gen-Fibro, Gemfibrozil; 1A Brand of Gemfibrozil; 2,2-Dimethyl-5-(2,5-dimethylphenoxy)pentanoic acid; 2,2-Dimethyl-5-(2,5-dimethylphenoxy)valeriansaeure; 2,2-Dimethyl-5-(2,5-xylyloxy)valeriansaeure; 2,2-Dimethyl-5-(2,5-xylyloxy)valeric acid; 5-(2,5-Dimethyl-Phenoxy)-2,2-Dimethyl-Pentanoic Acid; 5-(2,5-Dimethylphenoxy)-2,2-dimethylpentanoic acid; 5-[(2,5-dimethylphenyl)oxy]-2,2-dimethylpentanoic acid
Indication
Disease Entry ICD 11 Status REF
Hyperlipidaemia 5C80 Approved [1]
Therapeutic Class
Antilipemic Agents
Cross-matching ID
PubChem CID
3463
ChEBI ID
CHEMBL457
CAS Number
CAS 25812-30-0
TTD Drug ID
DMD8Q3J
VARIDT Drug ID
DR00540
INTEDE Drug ID
DR0766
ACDINA Drug ID
D00300

Molecule-Related Drug Atlas

Molecule-Related Drug Atlas
Molecule Type:
DTT
DME
DOT
Drug Status:
Approved Drug(s)
Clinical Trial Drug(s)
Investigative Drug(s)
Download the Complete Related Drug List
Drug(s) Targeting Lipoprotein lipase (LPL)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Clofibrate DMPC1J7 Dysbetalipoproteinemia 5C80.2 Approved [11]
AMT-011 DM8QIRN Blood forming organ disorder JB64.1 Phase 3 [12]
Ibrolipim DMOPWSX Hyperlipidaemia 5C80 Phase 2 [13]
WS-070117 DMYNIG5 Hyperlipidaemia 5C80 Investigative [12]
Drug(s) Metabolized By Cytochrome P450 3A4 (CYP3A4)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Doxorubicin DMVP5YE Acute myelogenous leukaemia 2A41 Approved [14]
Progesterone DMUY35B Amenorrhea GA20.0 Approved [15]
Tamoxifen DMLB0EZ Breast cancer 2C60-2C65 Approved [16]
Estradiol DMUNTE3 Acne vulgaris ED80 Approved [17]
Acetaminophen DMUIE76 Allergic rhinitis CA08.0 Approved [18]
Imatinib DM7RJXL Acute lymphoblastic leukaemia 2A85 Approved [19]
Etoposide DMNH3PG Acute myelogenous leukaemia 2A41 Approved [20]
Zidovudine DM4KI7O Human immunodeficiency virus infection 1C62 Approved [21]
Prasterone DM67VKL Chronic obstructive pulmonary disease CA22 Approved [15]
Verapamil DMA7PEW Angina pectoris BA40 Approved [22]
⏷ Show the Full List of 10 Drug(s)
Drug(s) Metabolized By UDP-glucuronosyltransferase 1A1 (UGT1A1)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Tamoxifen DMLB0EZ Breast cancer 2C60-2C65 Approved [23]
Estradiol DMUNTE3 Acne vulgaris ED80 Approved [24]
Acetaminophen DMUIE76 Allergic rhinitis CA08.0 Approved [25]
Etoposide DMNH3PG Acute myelogenous leukaemia 2A41 Approved [26]
Zidovudine DM4KI7O Human immunodeficiency virus infection 1C62 Approved [27]
Valproate DMCFE9I Epilepsy 8A60-8A68 Approved [28]
Mycophenolate mofetil DMPQAGE Hepatosplenic T-cell lymphoma Approved [29]
Metronidazole DMTIVEN Abscess Approved [30]
Propofol DMB4OLE Anaesthesia 9A78.6 Approved [31]
Ethanol DMDRQZU Chronic pain MG30 Approved [32]
⏷ Show the Full List of 10 Drug(s)
Drug(s) Metabolized By UDP-glucuronosyltransferase 2B7 (UGT2B7)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Tamoxifen DMLB0EZ Breast cancer 2C60-2C65 Approved [33]
Zidovudine DM4KI7O Human immunodeficiency virus infection 1C62 Approved [34]
Diclofenac DMPIHLS Chronic renal failure GB61.Z Approved [22]
Valproate DMCFE9I Epilepsy 8A60-8A68 Approved [35]
Mycophenolate mofetil DMPQAGE Hepatosplenic T-cell lymphoma Approved [36]
Ibuprofen DM8VCBE Dysmenorrhea GA34.3 Approved [22]
PITAVASTATIN CALCIUM DM1UJO0 Dyslipidemia 5C80-5C81 Approved [37]
Troglitazone DM3VFPD Diabetic complication 5A2Y Approved [38]
Ezetimibe DM7A8TW Atherosclerosis BD40 Approved [39]
Simvastatin DM30SGU Arteriosclerosis BD40 Approved [40]
⏷ Show the Full List of 10 Drug(s)
Drug(s) Metabolized By UDP-glucuronosyltransferase 1A3 (UGT1A3)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Diclofenac DMPIHLS Chronic renal failure GB61.Z Approved [41]
Valproate DMCFE9I Epilepsy 8A60-8A68 Approved [28]
Ibuprofen DM8VCBE Dysmenorrhea GA34.3 Approved [22]
Atorvastatin DMF28YC Acute coronary syndrome BA41 Approved [42]
Cerivastatin DMXCM7H Hyperlipidaemia 5C80 Approved [43]
PITAVASTATIN CALCIUM DM1UJO0 Dyslipidemia 5C80-5C81 Approved [37]
Troglitazone DM3VFPD Diabetic complication 5A2Y Approved [38]
Ezetimibe DM7A8TW Atherosclerosis BD40 Approved [44]
Simvastatin DM30SGU Arteriosclerosis BD40 Approved [40]
Losartan DM72JXH Diabetic kidney disease GB61.Z Approved [22]
⏷ Show the Full List of 10 Drug(s)
Drug(s) Metabolized By UDP-glucuronosyltransferase 1A9 (UGT1A9)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Acetaminophen DMUIE76 Allergic rhinitis CA08.0 Approved [45]
Diclofenac DMPIHLS Chronic renal failure GB61.Z Approved [41]
Sorafenib DMS8IFC Adenocarcinoma 2D40 Approved [46]
Valproate DMCFE9I Epilepsy 8A60-8A68 Approved [22]
Mycophenolate mofetil DMPQAGE Hepatosplenic T-cell lymphoma Approved [47]
Propofol DMB4OLE Anaesthesia 9A78.6 Approved [22]
Ibuprofen DM8VCBE Dysmenorrhea GA34.3 Approved [22]
Troglitazone DM3VFPD Diabetic complication 5A2Y Approved [48]
Nateglinide DMLK2QH Diabetic complication 5A2Y Approved [22]
Haloperidol DM96SE0 Delirium Approved [22]
⏷ Show the Full List of 10 Drug(s)
Drug(s) Affected By Aldo-keto reductase family 1 member B10 (AKR1B10)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Hydrogen peroxide DM1NG5W Infectious disease 1A00-CA43.1 Approved [49]
Clavulanate DM2FGRT Bacteremia 1A73 Approved [50]
Quercetin DM3NC4M Obesity 5B81 Approved [51]
Troglitazone DM3VFPD Diabetic complication 5A2Y Approved [52]
Rifampicin DM5DSFZ Non-insulin dependent diabetes 5A11 Approved [53]
Isoniazid DM5JVS3 Latent tuberculosis infection Approved [54]
Hydroquinone DM6AVR4 Melasma ED60.1 Approved [55]
Reserpine DM6VM38 Hypertension BA00-BA04 Approved [56]
Ciclosporin DMAZJFX Graft-versus-host disease 4B24 Approved [57]
Disulfiram DMCL2OK Alcohol dependence 6C40.2 Approved [58]
⏷ Show the Full List of 10 Drug(s)
Drug(s) Affected By Phospholipid-transporting ATPase ABCA1 (ABCA1)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Methotrexate DM2TEOL Anterior urethra cancer Approved [59]
Simvastatin DM30SGU Arteriosclerosis BD40 Approved [60]
Quercetin DM3NC4M Obesity 5B81 Approved [51]
Fluoxetine DM3PD2C Bipolar depression Approved [61]
obeticholic acid DM3Q1SM Primary biliary cholangitis DB96.1 Approved [62]
Troglitazone DM3VFPD Diabetic complication 5A2Y Approved [63]
Omeprazole DM471KJ Cystic fibrosis CA25 Approved [64]
Tretinoin DM49DUI Acne vulgaris ED80 Approved [65]
Rifampicin DM5DSFZ Non-insulin dependent diabetes 5A11 Approved [66]
Arsenic trioxide DM61TA4 Acute lymphoblastic leukaemia 2A85 Approved [67]
⏷ Show the Full List of 10 Drug(s)
Drug(s) Affected By Plasminogen activator inhibitor 1 (SERPINE1)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Cannabidiol DM0659E Dravet syndrome 8A61.11 Approved [68]
Hydrogen peroxide DM1NG5W Infectious disease 1A00-CA43.1 Approved [69]
Spironolactone DM2AQ5N Chronic heart failure BD1Z Approved [70]
Methotrexate DM2TEOL Anterior urethra cancer Approved [71]
Simvastatin DM30SGU Arteriosclerosis BD40 Approved [72]
Quercetin DM3NC4M Obesity 5B81 Approved [73]
obeticholic acid DM3Q1SM Primary biliary cholangitis DB96.1 Approved [62]
Troglitazone DM3VFPD Diabetic complication 5A2Y Approved [74]
Nefazodone DM4ZS8M Major depressive disorder 6A70.3 Approved [75]
Arsenic trioxide DM61TA4 Acute lymphoblastic leukaemia 2A85 Approved [76]
⏷ Show the Full List of 10 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas
Download the Complete Interaction Atlas for Visualization in Cytoscape

Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Lipoprotein lipase (LPL) TTOF3WZ LIPL_HUMAN Activator [2]

Drug-Metabolizing Enzyme (DME)
DME Name DME ID UniProt ID MOA REF
Cytochrome P450 3A4 (CYP3A4) DE4LYSA CP3A4_HUMAN Substrate [3]
UDP-glucuronosyltransferase 1A1 (UGT1A1) DEYGVN4 UD11_HUMAN Substrate [4]
UDP-glucuronosyltransferase 2B7 (UGT2B7) Main DME DEB3CV1 UD2B7_HUMAN Substrate [4]
UDP-glucuronosyltransferase 1A9 (UGT1A9) DE85D2P UD19_HUMAN Substrate [4]
UDP-glucuronosyltransferase 1A3 (UGT1A3) DEF2WXN UD13_HUMAN Substrate [5]
Catechol-2,3-dioxygenase (caD) DEFKSVZ A0A371SLU3_9BACI Substrate [6]

Drug Off-Target (DOT)
DOT Name DOT ID UniProt ID Interaction REF
Aldo-keto reductase family 1 member B10 (AKR1B10) OTOA4HTH AK1BA_HUMAN Gene/Protein Processing [7]
Phospholipid-transporting ATPase ABCA1 (ABCA1) OT94G6BQ ABCA1_HUMAN Gene/Protein Processing [8]
Plasminogen activator inhibitor 1 (SERPINE1) OTT0MPQ3 PAI1_HUMAN Gene/Protein Processing [9]
UDP-glucuronosyltransferase 1A1 OTH1C8OJ UD11_HUMAN Gene/Protein Processing [10]

References

1 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 3439).
2 Mode of action of fibrates in the regulation of triglyceride and HDL-cholesterol metabolism. Drugs Today (Barc). 2006 Jan;42(1):39-64.
3 Clinical pharmacokinetics of fibric acid derivatives (fibrates). Clin Pharmacokinet. 1998 Feb;34(2):155-62.
4 The UDP-glucuronosyltransferase 2B7 isozyme is responsible for gemfibrozil glucuronidation in the human liver. Drug Metab Dispos. 2007 Nov;35(11):2040-4.
5 Comprehensive pharmacogenomic study reveals an important role of UGT1A3 in montelukast pharmacokinetics. Clin Pharmacol Ther. 2018 Jul;104(1):158-168.
6 Genomic, proteomic, and metabolite characterization of gemfibrozil-degrading organism Bacillus sp. GeD10. Environ Sci Technol. 2016 Jan 19;50(2):744-55.
7 Inhibiting wild-type and C299S mutant AKR1B10; a homologue of aldose reductase upregulated in cancers. Eur J Pharmacol. 2008 Apr 28;584(2-3):213-21.
8 On the mechanism for PPAR agonists to enhance ABCA1 gene expression. Atherosclerosis. 2009 Aug;205(2):413-9. doi: 10.1016/j.atherosclerosis.2009.01.008. Epub 2009 Jan 19.
9 Effects of fibrate compounds on expression of plasminogen activator inhibitor-1 by cultured endothelial cells. Arterioscler Thromb Vasc Biol. 1999 Jun;19(6):1577-81. doi: 10.1161/01.atv.19.6.1577.
10 Comparative effects of fibrates on drug metabolizing enzymes in human hepatocytes. Pharm Res. 2005 Jan;22(1):71-8.
11 Effects of clofibrate treatment in laying hens. Poult Sci. 2007 Jun;86(6):1187-95.
12 Alipogene tiparvovec for the treatment of lipoprotein lipase deficiency. Drugs Today (Barc). 2013 Mar;49(3):161-70.
13 NO-1886 (ibrolipim), a lipoprotein lipase activator, increases the expression of uncoupling protein 3 in skeletal muscle and suppresses fat accumulation in high-fat diet-induced obesity in rats. Metabolism. 2005 Dec;54(12):1587-92.
14 Expression levels and activation of a PXR variant are directly related to drug resistance in osteosarcoma cell lines. Cancer. 2007 Mar 1;109(5):957-65.
15 Contribution of human hepatic cytochrome P450 isoforms to regioselective hydroxylation of steroid hormones. Xenobiotica. 1998 Jun;28(6):539-47.
16 Comprehensive evaluation of tamoxifen sequential biotransformation by the human cytochrome P450 system in vitro: prominent roles for CYP3A and CYP2D6. J Pharmacol Exp Ther. 2004 Sep;310(3):1062-75.
17 Isoform-specific regulation of cytochromes P450 expression by estradiol and progesterone. Drug Metab Dispos. 2013 Feb;41(2):263-9.
18 Metabolic interactions between acetaminophen (paracetamol) and two flavonoids, luteolin and quercetin, through in-vitro inhibition studies. J Pharm Pharmacol. 2017 Dec;69(12):1762-1772.
19 Potent mechanism-based inhibition of CYP3A4 by imatinib explains its liability to interact with CYP3A4 substrates. Br J Pharmacol. 2012 Apr;165(8):2787-98.
20 Effects of morin on the pharmacokinetics of etoposide in rats. Biopharm Drug Dispos. 2007 Apr;28(3):151-6.
21 The metabolism of zidovudine by human liver microsomes in vitro: formation of 3'-amino-3'-deoxythymidine. Biochem Pharmacol. 1994 Jul 19;48(2):267-76.
22 Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675.
23 Functional significance of UDP-glucuronosyltransferase variants in the metabolism of active tamoxifen metabolites. Cancer Res. 2009 Mar 1;69(5):1892-900.
24 Functional characterization of human and cynomolgus monkey UDP-glucuronosyltransferase 1A1 enzymes. Life Sci. 2010 Aug 14;87(7-8):261-8.
25 Effect of UDP-glucuronosyltransferase (UGT) 1A polymorphism (rs8330 and rs10929303) on glucuronidation status of acetaminophen. Dose Response. 2017 Sep 11;15(3):1559325817723731.
26 UDP-glucuronosyltransferase 1A1 is the principal enzyme responsible for etoposide glucuronidation in human liver and intestinal microsomes: structural characterization of phenolic and alcoholic glucuronides of etoposide and estimation of enzyme kinetics. Drug Metab Dispos. 2007 Mar;35(3):371-80.
27 Interindividual variability in pharmacokinetics of generic nucleoside reverse transcriptase inhibitors in TB/HIV-coinfected Ghanaian patients: UGT2B7*1c is associated with faster zidovudine clearance and glucuronidation. J Clin Pharmacol. 2009 Sep;49(9):1079-90.
28 Effect of aging on glucuronidation of valproic acid in human liver microsomes and the role of UDP-glucuronosyltransferase UGT1A4, UGT1A8, and UGT1A10. Drug Metab Dispos. 2009 Jan;37(1):229-36.
29 Characterization of rat intestinal microsomal UDP-glucuronosyltransferase activity toward mycophenolic acid. Drug Metab Dispos. 2006 Sep;34(9):1632-9.
30 Drug-drug interactions for UDP-glucuronosyltransferase substrates: a pharmacokinetic explanation for typically observed low exposure (AUCi/AUC) ratios. Drug Metab Dispos. 2004 Nov;32(11):1201-8.
31 Substrate-dependent modulation of UDP-glucuronosyltransferase 1A1 (UGT1A1) by propofol in recombinant human UGT1A1 and human liver microsomes. Basic Clin Pharmacol Toxicol. 2007 Sep;101(3):211-4.
32 Identification and preliminary characterization of UDP-glucuronosyltransferases catalyzing formation of ethyl glucuronide. Anal Bioanal Chem. 2014 Apr;406(9-10):2325-32.
33 Metabolism and transport of tamoxifen in relation to its effectiveness: new perspectives on an ongoing controversy. Future Oncol. 2014 Jan;10(1):107-22.
34 Determination of UDP-glucuronosyltransferase UGT2B7 activity in human liver microsomes by ultra-performance liquid chromatography with MS detection. J Chromatogr B Analyt Technol Biomed Life Sci. 2008 Jul 1;870(1):84-90.
35 Pharmacokinetic and pharmacodynamic interaction of lorazepam and valproic acid in relation to UGT2B7 genetic polymorphism in healthy subjects. Clin Pharmacol Ther. 2008 Apr;83(4):595-600.
36 PharmGKB summary: mycophenolic acid pathway. Pharmacogenet Genomics. 2014 Jan;24(1):73-9.
37 Pitavastatin: a review in hypercholesterolemia. Am J Cardiovasc Drugs. 2017 Apr;17(2):157-168.
38 Troglitazone glucuronidation in human liver and intestine microsomes: high catalytic activity of UGT1A8 and UGT1A10. Drug Metab Dispos. 2002 Dec;30(12):1462-9.
39 Ezetimibe: a review of its metabolism, pharmacokinetics and drug interactions. Clin Pharmacokinet. 2005;44(5):467-94.
40 Pharmacogenomics of statins: understanding susceptibility to adverse effects. Pharmgenomics Pers Med. 2016 Oct 3;9:97-106.
41 Glucuronidation of nonsteroidal anti-inflammatory drugs: identifying the enzymes responsible in human liver microsomes. Drug Metab Dispos. 2005 Jul;33(7):1027-35.
42 UGT1A1*28 is associated with decreased systemic exposure of atorvastatin lactone. Mol Diagn Ther. 2013 Aug;17(4):233-7.
43 Cerivastatin, genetic variants, and the risk of rhabdomyolysis. Pharmacogenet Genomics. 2011 May;21(5):280-8.
44 Drug interactions between the immunosuppressant tacrolimus and the cholesterol absorption inhibitor ezetimibe in healthy volunteers. Clin Pharmacol Ther. 2011 Apr;89(4):524-8.
45 Polymorphic expression of UGT1A9 is associated with variable acetaminophen glucuronidation in neonates: a population pharmacokinetic and pharmacogenetic study. Clin Pharmacokinet. 2018 Oct;57(10):1325-1336.
46 Pharmacokinetic interaction involving sorafenib and the calcium-channel blocker felodipine in a patient with hepatocellular carcinoma. Invest New Drugs. 2011 Dec;29(6):1511-4.
47 The evolution of population pharmacokinetic models to describe the enterohepatic recycling of mycophenolic acid in solid organ transplantation and autoimmune disease. Clin Pharmacokinet. 2011 Jan;50(1):1-24.
48 The UDP-glucuronosyltransferase 1A9 enzyme is a peroxisome proliferator-activated receptor alpha and gamma target gene. J Biol Chem. 2003 Apr 18;278(16):13975-83.
49 Time series analysis of oxidative stress response patterns in HepG2: a toxicogenomics approach. Toxicology. 2013 Apr 5;306:24-34.
50 Molecular mechanisms of hepatotoxic cholestasis by clavulanic acid: Role of NRF2 and FXR pathways. Food Chem Toxicol. 2021 Dec;158:112664. doi: 10.1016/j.fct.2021.112664. Epub 2021 Nov 9.
51 Comparison of phenotypic and transcriptomic effects of false-positive genotoxins, true genotoxins and non-genotoxins using HepG2 cells. Mutagenesis. 2011 Sep;26(5):593-604.
52 Transcriptomic analysis of untreated and drug-treated differentiated HepaRG cells over a 2-week period. Toxicol In Vitro. 2015 Dec 25;30(1 Pt A):27-35.
53 Identification of approved drugs as potent inhibitors of pregnane X receptor activation with differential receptor interaction profiles. Arch Toxicol. 2018 Apr;92(4):1435-1451.
54 Characterization of drug-specific signaling between primary human hepatocytes and immune cells. Toxicol Sci. 2017 Jul 1;158(1):76-89.
55 Keratinocyte-derived IL-36gama plays a role in hydroquinone-induced chemical leukoderma through inhibition of melanogenesis in human epidermal melanocytes. Arch Toxicol. 2019 Aug;93(8):2307-2320.
56 Oxidative stress mechanisms do not discriminate between genotoxic and nongenotoxic liver carcinogens. Chem Res Toxicol. 2015 Aug 17;28(8):1636-46.
57 Integrative "-Omics" analysis in primary human hepatocytes unravels persistent mechanisms of cyclosporine A-induced cholestasis. Chem Res Toxicol. 2016 Dec 19;29(12):2164-2174.
58 Keratinocyte gene expression profiles discriminate sensitizing and irritating compounds. Toxicol Sci. 2010 Sep;117(1):81-9.
59 Atheroprotective effects of methotrexate on reverse cholesterol transport proteins and foam cell transformation in human THP-1 monocyte/macrophages. Arthritis Rheum. 2008 Dec;58(12):3675-83.
60 Combining simvastatin with the farnesyltransferase inhibitor tipifarnib results in an enhanced cytotoxic effect in a subset of primary CD34+ acute myeloid leukemia samples. Clin Cancer Res. 2009 May 1;15(9):3076-83. doi: 10.1158/1078-0432.CCR-08-3004. Epub 2009 Apr 21.
61 Screening autism-associated environmental factors in differentiating human neural progenitors with fractional factorial design-based transcriptomics. Sci Rep. 2023 Jun 29;13(1):10519. doi: 10.1038/s41598-023-37488-0.
62 Pharmacotoxicology of clinically-relevant concentrations of obeticholic acid in an organotypic human hepatocyte system. Toxicol In Vitro. 2017 Mar;39:93-103.
63 Differential effects of peroxisome proliferator-activated receptor activators on the mRNA levels of genes involved in lipid metabolism in primary human monocyte-derived macrophages. Metabolism. 2003 May;52(5):652-7. doi: 10.1053/meta.2003.50100.
64 Proton pump inhibitor lansoprazole is a nuclear liver X receptor agonist. Biochem Pharmacol. 2010 May 1;79(9):1310-6. doi: 10.1016/j.bcp.2009.12.018. Epub 2010 Jan 8.
65 Repression of hepatocyte nuclear factor 4 alpha by AP-1 underlies dyslipidemia associated with retinoic acid. J Lipid Res. 2019 Apr;60(4):794-804. doi: 10.1194/jlr.M088880. Epub 2019 Feb 1.
66 Pregnane X receptor-agonists down-regulate hepatic ATP-binding cassette transporter A1 and scavenger receptor class B type I. Biochem Biophys Res Commun. 2005 Jun 17;331(4):1533-41. doi: 10.1016/j.bbrc.2005.04.071.
67 Inhibition of liver x receptor/retinoid X receptor-mediated transcription contributes to the proatherogenic effects of arsenic in macrophages in vitro. Arterioscler Thromb Vasc Biol. 2010 Jun;30(6):1228-36. doi: 10.1161/ATVBAHA.110.205500. Epub 2010 Mar 25.
68 Decrease of plasminogen activator inhibitor-1 may contribute to the anti-invasive action of cannabidiol on human lung cancer cells. Pharm Res. 2010 Oct;27(10):2162-74. doi: 10.1007/s11095-010-0219-2. Epub 2010 Jul 29.
69 Unique signatures of stress-induced senescent human astrocytes. Exp Neurol. 2020 Dec;334:113466. doi: 10.1016/j.expneurol.2020.113466. Epub 2020 Sep 17.
70 Effect of spironolactone on impaired fibrinolysis of hypertensive patients. Kidney Blood Press Res. 2002;25(4):260-4. doi: 10.1159/000066348.
71 Association of cell cycle arrest with anticancer drug-induced epithelial-mesenchymal transition in alveolar epithelial cells. Toxicology. 2019 Aug 1;424:152231. doi: 10.1016/j.tox.2019.06.002. Epub 2019 Jun 4.
72 Simvastatin inhibits tissue factor and plasminogen activator inhibitor-1 secretion by peripheral blood mononuclear cells in patients with primary nephrotic syndrome. Eur J Med Res. 2007 May 29;12(5):216-21.
73 Polyphenols downregulate PAI-1 gene expression in cultured human coronary artery endothelial cells: molecular contributor to cardiovascular protection. Thromb Res. 2007;121(1):59-65. doi: 10.1016/j.thromres.2007.02.001. Epub 2007 Mar 26.
74 Troglitazone reduces plasminogen activator inhibitor-1 expression and secretion in cultured human adipocytes. Diabetologia. 2000 Mar;43(3):377-83. doi: 10.1007/s001250050057.
75 Robustness testing and optimization of an adverse outcome pathway on cholestatic liver injury. Arch Toxicol. 2020 Apr;94(4):1151-1172. doi: 10.1007/s00204-020-02691-9. Epub 2020 Mar 10.
76 Arsenic trioxide induces different gene expression profiles of genes related to growth and apoptosis in glioma cells dependent on the p53 status. Mol Biol Rep. 2008 Sep;35(3):421-9.